Viridian Therapeutics' VRDN-001 demonstrates rapid efficacy in TED. Read why VRDN stock may benefit from FDA approval and market differentiation.

With these positive results on hand from both THRIVE and THRIVE-2, the company is aiming to file a BLA of veligrotug for the treatment of patients with chronic and active TED in the 2nd half of 2025.

S.BIOMEDICS reported that TED-A9, an investigational cell therapy for Parkinson's disease, showed positive data during the Phase 1/2a trial.